A chronological record of peer-reviewed Sermorelin research — trial types, sample sizes, and measured outcomes. This page summarizes what has been studied, not what users should expect to experience.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Peptide research timelines are often misrepresented online. Claims about "how quickly Sermorelinworks" usually blend anecdotal reports with selective trial data. This page restricts itself to what peer-reviewed studies measured, over what duration, with what sample size, and what the authors concluded. Readers should not infer personal results from these numbers.
Primary mechanism studied: GHRH Receptor Agonism. Primary indications investigated: Growth hormone stimulation, Anti-aging, Sleep quality, Body composition.
Body composition and metabolic study of sermorelin in obese men (BMI >30), measuring fat loss and metabolic parameters.
Study examining sermorelin responsiveness across BMI categories, testing whether obesity impairs GHRH-mediated GH secretion.
Double-blind trial evaluating sermorelin in older adults (>60 years) with documented low IGF-1 levels.
Study of sermorelin in older adults with impaired fasting glucose, assessing pancreatic insulin secretion and glucose homeostasis.
Bone densitometry study comparing sermorelin versus GH replacement on bone mineral density changes in GH-deficient adults.
Study examining sermorelin effects on body composition, lipid metabolism, and insulin sensitivity in healthy older adults (60-80 years).
Randomized trial evaluating sermorelin dose-response and optimal dosing regimens in adults with age-related GH decline.
Study of sermorelin effects on hypothalamic-pituitary-thyroid axis function in older adults with subclinical hypothyroidism.
Mechanistic study demonstrating GHRH receptor expression on pancreatic beta cells and direct sermorelin stimulation of insulin secretion.
Intensive GH profiling study documenting effects of sermorelin on spontaneous GH pulse frequency, amplitude, and basal secretion.
Subgroup analysis of sermorelin trials evaluating predictors of response across diverse age, body composition, and baseline hormone levels.
Mechanistic study demonstrating sermorelin overcomes somatostatin inhibition of GH secretion in pituitary cell culture.
Extended follow-up of sermorelin-treated GH-deficient children assessing long-term efficacy, compliance, and late adverse events.
Sleep polysomnography study examining sermorelin effects on sleep stages, REM sleep, and sleep continuity in GH-deficient patients.
Two-year study showing sermorelin maintained elevated IGF-1 levels and improved body composition in GH-deficient adults.
24-hour sampling study examining sermorelin restoration of GH secretion circadian rhythm and effects on cortisol patterns.
Long-term RCT comparing sermorelin acetate twice-daily subcutaneous injection versus placebo in growth hormone-deficient children.
Cellular study demonstrating sermorelin binding and G-protein coupling to GHRH receptors on cultured pituitary somatotroph cells.
The presence of a study does not mean an effect is established. Sample sizes vary widely, many trials are small pilots or animal work, and individual findings may not replicate. The overall evidence level for Sermorelin is L4 (Strong Clinical Evidence): multiple controlled human clinical trials with replicable data. Treat each study as one data point, not a conclusion.
PeptideMark indexes 51 studies on Sermorelin: 22 human studies, 15 animal studies, 4 in-vitro, and 10 reviews. The current evidence level is L4 — strong clinical evidence.
The earliest indexed peer-reviewed study on Sermorelin in the PeptideMark library was published in 1992 (Neuroendocrinology). Research activity has continued through 2005.
Duration varies by indication and phase. Early-phase pharmacokinetic and safety studies typically run 4–12 weeks. Phase 2 efficacy trials commonly span 12–26 weeks. Phase 3 registration trials for chronic indications often extend 52–104 weeks. Review individual trial records on ClinicalTrials.gov for specific durations.
Published research activity on Sermorelin has slowed in recent years based on indexed studies. Ongoing investigator-initiated trials may exist that are not yet indexed.
Every study referenced here links to its PubMed record via the study ID. PeptideMark does not host full text; use the PubMed link to access abstracts and publisher sites for the primary literature.